|
Wednesday 13th December 2023 |
Text too small? |
Rua Bioscience proudly announce the strategic appointment of Mr. John Sanders as the Chief of Sales and Marketing for Australia, marking a pivotal moment as he becomes the first Australian employee of Rua Bioscience.
Mr. Sanders, with a rich background in the cannabis sector, brings a wealth of experience to Rua Bioscience. His noteworthy three-year tenure at Cannasouth Bioscience, a NZ-based medicinal cannabis company, coupled with his extensive commercial experience in the pharmaceutical sector, including roles at Roche, Bayer, Merk and Sharp & Dome, uniquely positions him for success in this dynamic role.
As Rua Bioscience embarks on strategic expansion in the Australian market, Mr. Sanders will play a crucial role in overseeing sales and marketing operations from Melbourne. His appointment is a key step in our strategy to broaden our presence and reach in growing the Australian medicinal cannabis market.
Expressing his optimism, Paul Naske, CEO of Rua Bioscience, commented: "The appointment of John as Chief of Sales and Marketing for Australia is a significant milestone for Rua Bioscience. His impressive pharmaceutical and industry track record align seamlessly with our growth strategy in Australia. Under John’s leadership, we are confident in the success of our sales and marketing endeavours in this strategically important market”.
Rua Bioscience remains committed to delivering value through strategic appointments and expansion initiatives. The company looks forward to the positive impact Mr. Sanders will undoubtably bring to operations in Australia.
ENDS
No comments yet
VHP - Half year results announcement date and webcast details
Devon Funds Morning Note - 30 January 2026
AIA - Auckland Airport new board appointment
General Capital (GEN:NZ) Subsidiary General Finance Update
January 30th Morning Report
January 29th Morning Report
VSL - Date for 1H FY26 results announcement
January 28th Morning Report
IKE - Webinar Notification IKE Q3 FY26 Performance Update
VHP - Preliminary unaudited portfolio valuations 31 December 2025